SCHEDULE: Federated Hermes Maintains 10.76% Stake in aTYR Pharma

Federated Hermes, Inc. and affiliated entities reported continued beneficial ownership of 10.76% of aTYR Pharma Inc.'s common stock as a passive investor.

Summary

• Federated Hermes, Inc. and its affiliates, including the Voting Shares Irrevocable Trust and its trustees (Thomas R. Donahue, Ann C. Donahue, J. Christopher Donahue), beneficially own 10,544,437 shares of aTYR Pharma Inc. common stock.
• This ownership represents 10.76% of the total class of securities.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of aTYR Pharma Inc.
• Federated Hermes, Inc. functions as a parent holding company for investment advisers to registered investment companies and separate accounts that own these shares.
• The Voting Shares Irrevocable Trust holds all of Federated Hermes, Inc.'s outstanding voting stock, with the Donahues serving as trustees.

Sentiment

Score: 5

Explanation: This is a routine beneficial ownership disclosure (Schedule 13G Amendment No. 10) by a passive institutional investor. It provides factual information about ownership percentages and intent, without containing performance metrics, strategic updates, or other information that would typically influence a positive or negative sentiment score.

Positives

• A significant and stable institutional ownership stake (10.76%) by Federated Hermes, Inc. and its affiliates suggests a long-term investment perspective.
• The declaration that the securities are held in the ordinary course of business and not for control purposes indicates a passive, non-disruptive investment.

Negatives

• No specific negative information regarding aTYR Pharma Inc. is disclosed in this beneficial ownership report.

Risks

• No specific operational or financial risks for aTYR Pharma Inc. are mentioned in this beneficial ownership filing.
• Concentration of ownership, while stated as passive, could theoretically influence future corporate actions if the investor's intent were to change, though the filing explicitly disclaims this.

Future Outlook

No forward-looking statements or guidance regarding aTYR Pharma Inc. are provided in this beneficial ownership report.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
• This statement should not be construed as an admission that they are the beneficial owners of the Reported Securities, and the Parent, the Trust, and each of the Trustees expressly disclaim beneficial ownership of the Reported Securities.

Industry Context

This filing is a routine disclosure of a significant passive ownership stake by an institutional investor in a publicly traded biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape for aTYR Pharma Inc.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake, potentially offering a sense of stability.
• Management: Awareness of a large, passive institutional investor on the shareholder register.

Key Dates

Keywords

aTYR Pharma, Federated Hermes, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Biotechnology, Passive Investment